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Abstract 
Background: Non-Plasmodium falciparum malaria infections are found in many parts of sub-Saharan Africa but little 
is known about their importance in pregnancy.
Methods: Blood samples were collected at first antenatal clinic attendance from 2526 women enrolled in a trial of 
intermittent screening and treatment of malaria in pregnancy (ISTp) versus intermittent preventive treatment (IPTp) 
conducted in Burkina Faso, The Gambia, Ghana and Mali. DNA was extracted from blood spots and tested for P. falci-
parum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale using a nested PCR test. Risk factors for a non-
falciparum malaria infection were investigated and the influence of these infections on the outcome of pregnancy 
was determined.
Results: P. falciparum infection was detected frequently (overall prevalence by PCR: 38.8 %, [95 % CI 37.0, 40.8]), with 
a prevalence ranging from 10.8 % in The Gambia to 56.1 % in Ghana. Non-falciparum malaria infections were found 
only rarely (overall prevalence 1.39 % [95 % CI 1.00, 1.92]), ranging from 0.17 % in the Gambia to 3.81 % in Mali. Ten 
non-falciparum mono-infections and 25 mixed falciparum and non-falciparum infections were found. P. malariae was 
the most frequent non-falciparum infection identified; P. vivax was detected only in Mali. Only four of the non-falcipa-
rum mono-infections were detected by microscopy or rapid diagnostic test. Recruitment during the late rainy season 
and low socio-economic status were associated with an increased risk of non-falciparum malaria as well as falciparum 
malaria. The outcome of pregnancy did not differ between women with a non-falciparum malaria infection and those 
who were not infected with malaria at first ANC attendance.
Conclusions: Non-falciparum infections were infrequent in the populations studied, rarely detected when present 
as a mono-infection and unlikely to have had an important impact on the outcome of pregnancy in the communities 
studied due to the small number of women infected with non-falciparum parasites.
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Background
Plasmodium falciparum is the dominant malaria parasite 
in most parts of sub-Saharan Africa and hence respon-
sible for most infections in pregnancy [1]. Plasmodium 
vivax is also a significant cause of maternal morbidity 
during pregnancy and of low birth weight in parts of Asia 
[2–5] and Latin America [6, 7], even though the parasite 
does not sequester in the placenta [8]. P. vivax has been 
reported from time to time in non-pregnant populations 
in sub-Saharan Africa, especially when polymerase chain 
reaction (PCR) assays have been used [9–11], but P. vivax 
infections are generally considered to be uncommon 
in sub-Saharan Africa because of the presence in a high 
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proportion of the population of Duffy antigen negative 
red cells which cannot be invaded by this malaria para-
site. P. vivax infections have been recorded only rarely 
during pregnancy in East or West Africa [12], although 
they are relatively prevalent in parts of Ethiopia [13]. In 
contrast, Plasmodium ovale and Plasmodium malariae 
are relatively common in many parts of East and West 
Africa causing a significant proportion of febrile malaria 
episodes [14] and asymptomatic infections [15]. However, 
very little is known about the potential impact of non-
falciparum malaria infections on pregnancy and there 
have been very few reports of non-falciparum infections 
in pregnant women from East or West Africa. Walker-
Abbey et al. [16] detected P. malariae and P. ovale in 6.9 
and 1.8 % of pregnant Cameroonian women respectively, 
nearly always in mixed infections with P. falciparum. 
Mockenhaupt et al. [17] reported an increased suscepti-
bility of pregnant Ghanaian women with alpha + thalas-
saemia to infection with P. malariae and Coldren et  al. 
[18] describe a relapsing case of P. ovale in a pregnant 
women which was probably acquired many years previ-
ously in East or West Africa.
Screening of pregnant women at ante-natal clinic 
(ANC) visits with a rapid diagnostic test (RDT) for 
malaria and treatment of those who are positive with 
artemisinin-based combination therapy, an approach 
termed intermittent screening and treatment (ISTp), is 
being considered as a potential approach to the control 
of malaria in some epidemiological situations such as low 
transmission areas where few women are likely to ben-
efit from currently recommended intermittent preventive 
treatment with sulfadoxine-pyrimethamine (IPTp-SP). 
However, there is concern that this approach may lead to 
some malaria infections, especially those present at low 
density, being missed and adversely affecting the out-
come of pregnancy. This is especially likely to be the case 
for non-falciparum infections which are often present at 
only a low density and for which many RDTs have poor 
sensitivity. For this reason, the prevalence of falciparum 
and non-falciparum infections at first ANC attendance 
was investigated in women enrolled in a trial of ISTp ver-
sus IPTp-SP conducted in four West African countries 
(Burkina Faso, The Gambia, Ghana and Mali) and deter-
mined how many of these infections were detected by an 
RDT.
Methods
Details of the way in which the trial of ISTp versus IPTp-
SP was conducted have been presented previously [19]. 
In brief, 5354 primigravid or secundigravid women 
were randomised individually at their first ANC visit to 
the ISTp or IPTp-SP group. Women in the ISTp group 
were screened for malaria with a RDT at enrollment 
and at each subsequent routine ANC visit and treated 
with artemether–lumefantrine (AL) if positive, whilst 
women in the IPTp group received a dose of SP at each 
routine ANC visit. Haemoglobin (Hb) concentration was 
determined at each woman’s final ANC visit, scheduled 
to occur between 36 and 40  weeks of gestation. Study 
women were encouraged to deliver in hospital where pla-
cental biopsies were obtained for histology and examined 
using a standardized protocol as described previously 
[19]. Birth weight was recorded at delivery in women 
who delivered in hospital and within 7 days of delivery in 
women who delivered at home. Infants and mothers were 
evaluated 6 weeks after birth.
The analysis reported in this paper is based on blood 
samples obtained at the first ANC visit from the 2526 
women in the ISTp-AL group. An RDT (First Response® 
Malaria Rapid Diagnostic Combo Test) was done and 
blood films and filter paper blots prepared. Blood films 
were examined for malaria parasites according to the 
methods described by Swysen et  al. [20]. PCR testing 
was conducted at the MRC Unit, The Gambia. Follow-
ing extraction of DNA from a filter paper blood spot, the 
first stage of this nested PCR test involves a PCR assay 
with the primers rPLU5  +  rPLU6. This assay includes 
positive controls for each of the four main malaria spe-
cies (P. falciparum, P. vivax, P. ovale and P. malariae) and 
a negative control without DNA. The second PCR reac-
tion detects the presence of Plasmodium infection using 
the genus specific primers Plasmo-1 and Plasmo-2. The 
third stage, undertaken on genus specific samples, deter-
mines species by running four parallel PCR assays using 
the following primers (P. falciparum: rFAL 1 + rFAL 2; P. 
malariae: rMAL 1 + rMAL 2; P. ovale: rOVA 1 + rOVA 
2; P. vivax:rVIV 1 + rVIV 2). For further differentiation of 
P. ovale into the two distinct species P. ovale curtisi and P. 
ovale wallikeri, the P. ovale sp. Tryptophan-rich antigen 
(PoTRA) nested PCR assay was used [21]. Quality control 
of the assays undertaken in The Gambia was undertaken 
at Duke University, North Carolina. The lower level of 
detection of the assay is approximately 10 parasites per 
µl. The sensitivity of microscopy and an RDT in detecting 
non-falciparum infections detected by PCR was explored.
The association between demographic and obstetric fac-
tors and the presence of falciparum and non-falciparum 
malaria infections was explored. A multi-variable logistic 
regression model was then built to explore risk factors for 
non-falciparum infection, controlling for potential con-
founding from other risk factors, using those without a 
malaria infection as the reference group. Women with fal-
ciparum malaria infection were excluded from the analysis, 
as many of the risk factors for P. falciparum and non-falci-
parum infections are likely to be shared. An exploratory 
analysis was conducted to investigate whether there was any 
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evidence of an association between non-falciparum malaria 
infections and the primary outcomes of the main trial: active 
malaria infection of the placenta, low birth weight and hae-
moglobin at the last ANC contact prior to delivery, again 
using those with no malaria infection as the reference group. 
The relationship with measured birth weight, an important 
secondary end-point for the trial, was also explored.
The trial which provided the samples for this study was 
approved by the London School of Hygiene and Tropi-
cal Medicine Ethical Committee and by the ethics com-
mittees of all the partner African institutions: Comité 
National d’Ethique pour la Recherche en Santé (CNERS), 
Burkina Faso; Ethics committee of the Ghana Health 
Service Committee Research & Development Divi-
sion, Ghana Health Science, Ghana; Navrongo Health 
Research Centre Institutional Review Board, Ghana; 
Comité d’éthique de la Faculté de la Faculté de Médecine 
et d’Odontostomatologie, Mali; The Gambia Govern-
ment/MRC Laboratories Joint Ethics Committee, The 
Gambia. Written informed consent was obtained from all 
participating women. The trial is registered with Clinical-
Trials.gov (NCT01084213) and the Pan African Clinical 
trials Registry (PACT201202000272122).
Results
PCR detected P. falciparum malaria in 981/2526 (38.8 %; 
95  % CI 37.0, 40.8) pregnant women at first ANC 
attendance (Table  1), but only 35 non-falciparum infec-
tions were detected, an overall prevalence of 1.39 % (95 % 
CI 1.00, 1.92) (Table 1). Ten of the non-falciparum infec-
tions were mono-infections and 25 were mixed infections 
with P. falciparum. Only three of the 10 mono-infections 
were detected by RDT and only three by microscopy (two 
infections were detected by both methods, and one each 
was detected by RDT and microscopy alone). In two of 
the latter cases, the microscopic diagnosis was P. falcipa-
rum. Twenty-three (92 %) of the 25 mixed P. falciparum 
and non-falciparum infections were detected by RDT, 
and 18 (72  %) were detected by microscopy, with the 
microscopic diagnosis being P. falciparum in all cases. 
Overall, only nine non-falciparum infections were missed 
by RDT and 14 missed by microscopy in 2526 pregnant 
women.
Plasmodium malariae was the most common non-
falciparum species detected, being present alone in 
three women (all from Mali) and in 14 mixed infections 
(11 with P. falciparum, and three with P. falciparum and 
P. ovale). Eleven mixed P. ovale and P. falciparum infec-
tions were detected. Both forms of P. ovale were found 
in roughly equal abundance (seven P. ovale curtisi, nine 
P. ovale wallikeri, and one either mixed infection of P. 
ovale curtisi with P. ovale wallikeri, or an indeterminate 
P. ovale infection). P. vivax was found in only four women 
(two mixed with P. falciparum), all of whom lived in Mali. 
Table 1 Falciparum and non-falciparum malaria infections detected in 2526 pregnant West African women at first ANC 
clinic attendance
Burkina Faso Gambia Ghana Mali Total
Number of women 695 604 624 603 2526
 Number of P. falciparum infections 377 65 350 189 981
 Prevalence of P. falciparum 54.2 % 10.8 % 56.1 % 31.3 % 38.8 %
 (95 % Confidence interval) (50.5, 57.9) (8.53, 13.5) (52.2, 59.9) (27.8, 35.2) (37.0, 40.8)
 Number of non-falciparum malaria infections overall 5 1 6 23 35
 Prevalence of non-falciparum malaria 0.72 % 0.17 % 0.96 % 3.81 % 1.39 %
 (95 % Confidence interval) (0.30, 1.72) (0.02, 1.17) (0.43, 2.13) (2.55, 5.68) (1.00, 1.92)
Number of mono-infections
 P. falciparum 374 65 345 172 956
 P. malariae 0 0 0 3 3
 P. vivax 0 0 0 2 2
 P. ovale curtisi 1 0 0 1 2
 P. ovale wallikeri 1 1 1 0 3
Mixed infections
 P. falciparum, P. malariae 0 0 1 10 11
 P. falciparum, P. ovale curtisi 1 0 1 1 3
 P. falciparum, P. ovale wallikeri 1 0 2 3 6
 P. falciparum, P. vivax 0 0 0 2 2
 P. falciparum, P. malariae, P. ovale curtisi 0 0 1 1 2
 P. falciparum, P. malariae, P. ovale wallikeri 1 0 0 0 1
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Because of the unexpected finding of P. vivax parasites 
in four black, African women resident near Bamako, the 
identity of these parasites was confirmed using a real-
time PCR assay targeting the P. vivax ribosomal RNA 
gene (S.R. Meshnick, personal communication).
There was variation in the prevalence of non-falcipa-
rum malaria between study sites, with Mali having the 
highest prevalence (3.81 % [95 % CI 2.55, 5.68]) compared 
with Ghana (0.96  % [95  % CI 0.43, 2.13]), Burkina Faso 
(0.72  % [95  % CI 0.30, 1.72]) and The Gambia (0.17  % 
[95 % CI 0.02, 1.17]).
There were no major differences in the prevalence of 
non-falciparum malaria infections overall according to 
gravidity, gestational age at enrolment, educational level 
or socio-economic status (Table  2). There was some 
suggestion of differences in the prevalence of non-falci-
parum malaria between age groups, although the statisti-
cal evidence for this was not strong. Relative to mothers 
below 18  years of age, the adjusted odds ratio [OR] for 
mothers aged 18–20 years was 3.77 (95 % CI 1.03, 13.8) 
(p  =  0.045) but there were no differences in older age 
groups compared to mothers below 18 years of age. Non-
falciparum malaria infections were more common among 
women in the two poorest socio-economic groups; 
adjusted OR relative to the wealthiest group (6.48 [95 % 
CI 1.68, 25.0] and 6.55 [95 % CI 1.27, 33.7]) in the poor 
Table 2 The prevalence of P. falciparum and non-falciparum malaria infections overall at first ANC visit according to base-
line characteristics
a Gestational age at enrolment assessed by symphysis-fundal height
b Educational level reported by the mother at the enrolment visit
c Season enrolled indicates the month of the year when the woman first presented to ANC and was enrolled into the study
d Socio-economic status defined using principal components analysis of durable household assets and household amenities, as described in [16]
Uninfected P. falciparum infection Non-falciparum infection
No. % No. % No. %
Gravidity
 Primigravid 754 54.7 605 43.9 20 1.5
 Secundigravid 736 64.8 385 33.9 15 1.3
Gestational agea
 <20 weeks 510 55.6 397 43.3 10 1.1
 20–24 weeks 794 59.9 509 38.4 23 1.7
 25–30 weeks 187 68.0 86 31.3 2 0.7
Age
 Under 18 years 194 61.4 119 37.7 3 0.9
 18–20 years 656 53.8 542 44.4 22 1.8
 21–24 years 434 64.4 234 34.7 6 0.9
 25 years + 211 66.8 101 32.0 4 1.3
Educational levelb
 1-none 689 59.6 452 39.1 15 1.3
 2-basic 557 56.3 416 42.0 17 1.7
 3-secondary 210 65.8 107 33.5 2 0.6
 4-tertiary 20 57.1 14 40.0 1 2.9
Season enrolledc
 Early wet (6–8) 614 69.6 261 29.6 7 0.8
 Late wet (9–11) 188 45.4 215 51.9 11 2.7
 Early dry (12–2) 251 46.5 282 52.2 7 1.3
 Late dry (3–5) 442 64.1 238 34.5 10 1.4
Socio-economic statusd
 1-wealthiest 375 77.8 99 20.5 8 1.7
 2-wealthy 325 67.8 142 29.6 12 2.5
 3-medium 262 54.5 217 45.1 2 0.4
 4-poor 230 48.0 241 50.3 8 1.7
 5-poorest 226 46.1 259 52.9 5 1.0
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and poorest groups respectively. As found in the previous 
analysis of P. falciparum infections in study women [16], 
non-falciparum malaria infections were more common 
among women who were enrolled in the late wet season 
(between September and November): adjusted OR 7.10 
(95 % CI 2.56, 19.7), p < 0.001 (Table 3). Following adjust-
ment for these other factors, the association between 
non-falciparum malaria and study centre was strength-
ened: relative to Ghana (the centre with the second high-
est prevalence), the adjusted OR for Mali was 6.54 (95 % 
CI 1.79, 23.9), p = 0.005 and for The Gambia 0.10 (95 % 
CI 0.01, 0.88) (p = 0.038). There remained no differences 
between Ghana and Burkina Faso, adjusted OR 0.53 
(95 % CI 0.14, 2.03) (p = 0.353).
The prevalence of active placental malaria infection at 
delivery was similar in those with a mono- or mixed non-
falciparum malaria infection and those with no infection: 
23.1 versus 21.8 % respectively, adjusted OR 1.63 (95 % CI 
0.58, 4.60), p =  0.356 (Table 4). Of the six women with 
a non-falciparum mono infection who also had a pla-
cental malaria result, only two had an active infection of 
the placenta (acute in both cases) and the infection was 
not noted to be one with a non-falciparum infection. 
Sections from four of these women showed pigment in 
fibrin and/or macrophages (three without malaria infec-
tion, one with malaria infection) and one mild inflam-
mation in a woman with malaria infection. Prevalence of 
low birth weight was similar between those with a mono- 
or mixed non-falciparum malaria infection and those 
with no malaria infection: 16.1 and 17.1  % respectively, 
adjusted odds ratio 0.95 (95 % CI 0.35, 2.58) (p = 0.915). 
Similarly, there was no evidence of a difference in mean 
birth weight between women with a mono- or mixed 
non-falciparum infection and those with no malaria 
infection during pregnancy: adjusted difference—51.9  g 
(95 % CI −220.8 g, +117.0 g) (p = 0.547), Table 4. Finally, 
measured Hb at the final ANC contact was also simi-
lar in those with no malaria infection (10.93  g/dL) and 
in those with a mono- or mixed non-falciparum infec-
tion (11.05 g/dL): adjusted difference 0.01 g/dL (95 % CI 
−0.55, + 0.56) (p = 0.983).
Discussion
This study confirmed that non-falciparum malaria infec-
tions are present in pregnant women in West Africa but 
that they are uncommon, with an overall prevalence 
across four countries of 1.4  % at first ANC attendance. 
It is likely that some additional infections occurred later 
in pregnancy. However, among the women from Ghana 
enrolled in this study who were followed throughout 
pregnancy, at least a half of all malaria infections were 
detected at the first ANC visit [22]; the figures for all 
ANC visits were 53.6 % for RDT, 60.6 % for microscopy 
and 64.3 % for PCR respectively. Thus, unless there is a 
differential rate of infection between non-falciparum 
and falciparum infections, it is likely that the prevalence 
of non-falciparum infections at any time point during 
the course of pregnancy would have been be low in the 
study population. Prevalence of non-falciparum infec-
tions varied between centres, being less than 1  % in 
Table 3 Risk factors for non-falciparum malaria infections 
overall at first ANC attendance
Crude ORs for gravidity, gestational age, age, education level, season of 
enrolment, and social economic status are adjusted for country as an a priori 
covariate. Adjusted ORs presented adjusted for all other covariates in the 
multivariable model. Gestational age at enrolment was assessed by symphysis-
fundal height. Educational level reported by the mother at the enrolment 
visit. Season enrolled indicates the month of the year when the woman first 
presented to ANC and was enrolled into the study. Socio-economic status 
defined using principal components analysis of durable household assets and 
household amenities, as described in [16]
Risk factor Crude OR  
(95 % CI)
p value Adjusted OR 
(95 % CI)
p value
Country
 Ghana [Reference] – [Reference] –
 Burkina Faso 0.74 (0.22, 2.46) 0.627 0.53 (0.14, 2.03) 0.353
 Gambia 0.08 (0.01, 0.69) 0.021 0.10 (0.01, 0.88) 0.038
 Mali 2.52 (1.01, 6.28) 0.047 6.54 (1.79, 23.9) 0.005
Gravidity
 Primigravid [Reference] – [Reference] –
 Secundigravid 0.85 (0.42, 1.69) 0.639 0.71 (0.33, 1.54) 0.386
Gestational age
 <20 weeks [Reference] – [Reference] –
 20–24 weeks 1.51 (0.70, 3.23) 0.290 1.92 (0.85, 4.31) 0.115
 25–30 weeks 0.57 (0.12, 2.64) 0.469 0.60 (0.12, 2.90) 0.521
Age
 Under 18 years [Reference] – [Reference] –
 18–20 years 2.98 (0.86, 10.3) 0.084 3.77 (1.03, 13.8) 0.045
 21–24 years 1.38 (0.32, 5.83) 0.665 2.14 (0.43, 10.6) 0.351
 25 years + 1.75 (0.36, 8.41) 0.484 2.54 (0.45, 14.3) 0.290
Education level
 1-none [Reference] – [Reference] –
 2-basic 0.92 (0.43, 1.96) 0.833 0.96 (0.41, 2.22) 0.924
 3-secondary 0.27 (0.06, 1.23) 0.092 0.27 (0.05, 1.32) 0.106
 4-tertiary 1.36 (0.17, 11.2) 0.774 3.73 (0.35, 40.2) 0.277
Season enrolled
 Early wet (6–8) [Reference] – [Reference] –
 Late wet(9–11) 5.59 (2.10, 14.9) 0.001 7.10 (2.56, 19.7) <0.001
 Early dry (12–2) 2.84 (0.97, 8.27) 0.056 2.54 (0.84, 7.67) 0.098
 Late dry(3–5) 1.76 (0.66, 4.69) 0.260 1.85 (0.68, 5.04) 0.228
SES
 1-wealthiest [Reference] – [Reference] –
 2-wealthy 2.14 (0.85, 5.34) 0.105 1.82 (0.68, 4.83) 0.230
 3-medium 1.07 (0.21, 5.33) 0.935 0.96 (0.18, 5.02) 0.963
 4-poor 6.30 (1.83, 21.7) 0.004 6.48 (1.68, 25.0) 0.007
 5-poorest 5.89 (1.35, 25.7) 0.018 6.55 (1.27, 33.7) 0.024
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three, but close to 4  % in Mali. These differences can-
not be explained solely by differences in the intensity of 
transmission between centres as Mali had the second 
lowest prevalence of P. falciparum infection of the four 
study sites. P. vivax was detected only in Mali, and only 
in one sub-site in suburban Bamako. This malaria para-
site is known to be present in northern Mali [10], perhaps 
because of some mixing with north African populations, 
but not in the southern parts of the country where all 
these infections were found. This unexpected finding is 
being followed up further.
The results of this study indicate the difficulty in iden-
tifying non-falciparum malaria infections by microscopy 
when these infections are encountered rarely and often 
present in mixed infections with P. falciparum: only three 
of the 10 pure non-falciparum infections were detected 
by microscopy, and two of these were mistaken for P. 
falciparum despite the fact that study slides were read 
by two well-trained microscopists and that the quality 
of microscopical reading was well controlled. In sub-
Saharan Africa, microscopists expect malaria infections 
present in a blood film to be due to P. falciparum and 
this may have influenced their recording of the results. 
Rapid diagnostic tests did not perform any better than 
microscopy, also missing seven of the 10 non-falciparum 
mono-infections, perhaps because these were present at 
only a low density. When P. falciparum was also present, 
RDTs detected all but two of these infections, whereas 
microscopy missed seven of the mixed infections. These 
findings suggest that when, in sub-Saharan Africa, detec-
tion of non-falciparum malaria infection in pregnancy 
depends upon microscopy, many non-falciparum infec-
tions will be missed. Factors likely to have contributed 
to the poor performance of microscopy and a RDT in 
detecting non-falciparum infections are their frequent 
occurrence as mixed infections with P. falciparum and 
their presence at only a low density. Why the latter 
should be the case is uncertain, but it may be due in part 
to suppression of the minor parasite by P. falciparum in 
mixed infections and in part due to the fact these may 
have been more chronic infections than those caused by 
P. falciparum.
Enrolment at the end of the wet season was a risk fac-
tor for non-falciparum malaria infection, as was lower 
socio-economic status. These are both well-established 
risk factors for malaria infection in general. The sug-
gestion of an association of one specific age group with 
higher risk of non-falciparum infections does not have a 
biological explanation and is likely to be a chance finding 
as the numbers of non-falciparum infections studied was 
small.
There was no association between the presence of a 
non-falciparum malaria infection at first ANC presenta-
tion and an adverse outcome of pregnancy. However, the 
number of non-falciparum infections was small, 26 of the 
35 individuals with non-falciparum infections at baseline 
Table 4 Association of  non-falciparum malaria overall with  birth outcomes including  placental malaria (PM), birth-
weight and haemoglobin concentration
Crude odds ratios/differences are adjusted for country as an a priori covariate. Adjusted odds ratios/differences also adjust for gravidity, gestational age, age, 
education level, season of enrolment, and social economic status
No malaria infection Non-falciparum infection
No. % No. %
No active PM 744 78.2 20 76.9
Active PM 207 21.8 6 23.1
Crude OR (95 % CI), p value [Reference] – 1.06 (0.41, 2.76) 0.90
Adjusted OR (95 % CI), p value [Reference] – 1.63 (0.58, 4.60) 0.36
Normal birth weight 1099 82.9 26 83.9
Low birth weight 227 17.1 5 16.1
Crude OR (95 % CI), p value [Reference] – 0.97 (0.36, 2.57) 0.94
Adjusted OR (95 % CI), p value [Reference] – 0.95 (0.35, 2.58) 0.92
Mean SD Mean SD
Birth weight (kg) 2.85 0.48 2.78 0.31
Crude difference, grammes (95 % CI), p value [Reference] – −57.7 (−227.7, 112.3) 0.51
Adjusted difference, grammes (95 % CI), p value [Reference] – −51.9 (−220.8, 117.0) 0.54
Hb at final ANC 10.93 1.36 11.05 1.16
Crude difference, g/dL (95 % CI), p value [Reference] – −0.09 (−0.64, 0.47) 0.76
Adjusted difference, g/dL (95 % CI), p value [Reference] – 0.01 (−0.55, 0.56) 0.98
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were treated with artemether-lumefantrine and it is pos-
sible that some women in the uninfected reference group 
were infected at later time points, diluting differences 
between the two groups, so this finding is not surprising.
This study was undertaken as part of an evaluation of 
ISTp because of concerns that a significant number of 
infections caused by non-falciparum species might be 
missed during RDT testing, with an adverse impact on 
the outcome of pregnancy, if this approach to malaria 
control in pregnancy was to be implemented. Because 
the majority of non-falciparum infections occurred 
in conjunction with a falciparum infection which was 
detected by a RDT, as noted in another recent study in 
Burkina Faso and Uganda (Hopkins et al. personal com-
munication), the majority of women with a non-falci-
parum infection received appropriate treatment; only 
seven non-falciparum mono-infections and two mixed 
non-falciparum and falciparum infections were missed at 
first ANC visit using a ‘combo’ RDT among 2526 women. 
For this reason the occurrence of non-falciparum infec-
tions is unlikely to be a concern should ISTp be recom-
mended for any population group in sub-Saharan Africa. 
However, this might not be the case in other parts of the 
malaria endemic world where non-falciparum infections, 
particularly those caused by P. vivax, are more prevalent 
and where many more infections might be missed using 
currently available RDTs.
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